Slingshot Insights is the first crowdfunded expert network and due diligence community. Members use our suite of tools to cut through the noise and Become the Smart Money. We provide you affordable access to Experts and Management Teams so that you can make informed investment decisions. By grouping investors around project ideas they care about, we pass along significant savings without compromising on quality.
It is very hard or impossible to time the broad market consistently — there are no famous investors that got rich by consistently knowing what the broad market would do next. This only makes sense, as there are just too many variables in the broad market. But there are many famous investors who got rich analyzing individual securities, and this is where you should put your focus. You can get an edge in individual securities. Joe Springer was the number 1 ranked stock analyst in the world by tipranks.com, and on most days is still ranked in the top 5%. Joe is a Certified Technical Trainer, and enjoys teaching about the stock market as well as managing portfolios. If you would like to follow Joe on Twitter, his handle is @JoeSpringer.
I am a medical professional, and I have worked as a consultant in the private equity and hedge fund industries.
I have particular interests and strengths in biotechnology, healthcare, pharmaceuticals with an oncology (cancer) focus. I have particular knowledge and expertise in catheters, medical devices and drugs used in interventional (special) procedures.
Having Texas tendrils, I also enjoy investing and have knowledge in the energy patch.
John Thomas graduated with a bachelor’s degree in biochemistry with honors and a minor in mathematics from the University of California at Los Angeles (U.C.L.A.) in 1974. He moved to Tokyo, Japan where he was employed by a medium-sized Japanese securities house. Thomas became fluent in Japanese and was trained as a domestic Japanese research analyst and money manager. In 1977 Thomas became the Tokyo correspondent for The Economist magazine and the Financial Times of London. Thomas traveled extensively throughout Asia, interviewing premiers, presidents and prime ministers, writing on macroeconomic trends, and producing countless features about individual companies. Thomas witnessed China’s cultural revolution and was one of the first American correspondents to enter China prior to the U.S. normalization of relations. Thomas authored several books about the Japanese financial system still in use by business schools today. In 1983 Thomas joined a top US investment bank in New York with the mandate to develop an international equity business for the firm. In 1985 he moved to London, England to establish a presence in Japanese equity derivatives for the firm. In 1989 Thomas was appointed a director of one of the big three Swiss Banks with a mandate to design sophisticated hedging strategies for the bank’s considerable holdings of Japanese equity warrants and convertible bonds. With the invasion of Kuwait by Iraq, Thomas was drafted by the US Marine Corp to serve as a pilot. In 1990 Thomas became a pioneer in the nascent hedge fund industry by founding the first dedicated Japanese hedge fund. The firm managed segregated accounts for a variety of government agencies, banks, and high net worth individuals in Europe, the Middle East, and Asia. After a decade of spectacular absolute and relative performance he sold his firm in 1999 and retired to manage his personal investments in the oil and gas industry. Seeing incredible opportunities in the marketplace and yearning for the adrenaline and satisfaction offered by active management, Thomas launched a new hedge fund in 2007. In his free time Thomas is a commercial aircraft pilot, long distance hiker and mountain climber, wine collector and avid photographer.
I am a medical professional that enjoys investing in biotech stocks. I take long positions and may dabble in options. I have a particular interest in biotechs with an ophthalmic (eye) focus as that is where I have developed the greatest expertise over my career and research. I hope over time to share some of my professional insights with those of the Seeking Alpha community in order to help them make more informed investing decisions. I expect to learn a lot from others as well.
I am long the following biotechs at this time: GILD, OPHT, CRMD, ACAD, RLYP, HALO, TGTX, APHB, ZIOP.
I am advising everyone to avoid: OHRP
For the past 30 years, I have been involved in startups, as a founder, and active investor. My first company was purchased by Johnson & Johnson, which set the foundation for future investments.
My level of trading escalated after graduating from college, primarily as a result of my relationship with the founder of the Silicon Valley venture capital firm, Institutional Venture Partners, (Netflix, Twitter, Oracle). By focusing on VC backed companies, I soon learned the advantage of investing in promising companies before they became household names. My interest in startups has never waned, and has become my primary focus today.
I am a private investor based out of Toronto, Canada and I have been investing since 2003. After 8 years in Corporate Finance with a Canadian Telecom company I have decided to dedicate myself full-time to the capital markets. I write on Seeking Alpha to demonstrate my financial analysis and writing skills across a variety of industries and to take advantage of any story-based trading opportunity that may arise. My passion and greatest depth of knowledge is on Canadian small cap stocks and I consider my blog posts to be some of my best work. I am interested in any freelance opportunities that may arise outside of Seeking Alpha on Canadian or American listed stocks.
I added stock and bond analysis to my IT consulting business at the request of a small cap investment specialist in 2002. For my own account I invest mainly in technology and biotechnology stocks, but occasionally I invest in industrial, retail and other stocks. My technology and investment web site is openicon.com. I still enjoy IT consulting and always have some sort of R&D project going on.
Investor, Writer, Runner
I am especially interested in small/microcap stocks. Not only are they more capable of generating massive returns, but they provide the individual investor with a more level playing field than many larger cap companies.
To follow me click the "Follow" button! (Easy right?) Kumquat Research is a college student and fund manager who has been investing for 4 years. He writes mostly about the technology sector and about event-driven and momentum opportunities across various industries and sectors. He is currently studying for degrees in both finance and computer science at the University of Maryland. Some of his interests include technology, software engineering, drumming, video games (developing and playing) and astronomy.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
10 years investing in $10 or less stocks. My portfolio has grown from an initial $4K investment to well over a million in that period of time. I specialize in identifying under-the-radar, unloved stocks with great upside.
6 years in investment banking at Bulge bracket, 2 years at Italian Bank, 1.5 year at Hedge Fund
Engineer, MBA, CFA Charterholder
10 years total in Financial markets
Currently managing personal assets: mainly biotech, banks, value stocks, event situations
I am a psychologist at the University of Massachusetts/Amherst. I am on our campus’s Institutional Review Board, which must conclude that proposed studies involving human subjects are conducted ethically and are designed well enough so that any risks involved are justified by the likely benefits obtained.
I teach about analytical reasoning, leadership skills, reconciling apparently incompatible positions, designing, implementing, and evaluating policies, and how to critically evaluate competing health claims based on the samples studied and methods of data collection and analysis used.
Most of my investments involve owning medical industry stocks.
A former writer for the TheStreet and SA, I'm an ardent follower of financial markets and macro-developments and enjoy disseminating research and due diligence in an effort to both spark ideas for alpha and to help corroborate the findings of others. I focus on both nascent companies with potential that are well managed as well as blue-chip stalwarts that are either undervalued or possess long-term earnings growth.
Individual investor - with background in pharma, intellectual property, legal, regulatory, business and related strategic initiatives. President of PersisPharma LLC, since October 2014. PersisPharma is engaged in exploratory pharmaceutical research and related product development.
TipRanks is the most comprehensive data set of sell side analysts, hedge fund managers, financial bloggers, and corporate insiders. We rank financial experts based on measured performance and the accuracy of their predictions. We aim to make Wall Street more transparent by highlighting which experts can consistently outperform the market, allowing investors to make the most informed investment decisions.
EXP is a graduate from The University of Wall Street and serves as the CEO / Chief Stock Strategist at EXPstocktrader.com research firm.
With over 30 years of trading the market, EXP is an experienced investor using a fundamental and technical approach as a market analyst, chartist, visual analyst, as well as, a trader, author, coach, and serial entrepreneur. Extremely dedicated by investing countless hours investigating, analyzing, then writing about unique stock opportunities, as well as, coaching existing followers worldwide. EXP delivers "Real Facts" to Seeking Alpha and Twitter followers on monthly stock selections. Not all of the research found in the EXPstocktrader Monthly Newsletter is openly published online so EXP's members get updates first. Note: Most stocks covered have a unique niche or value proposition.
The Goal is to assist the small to mid-level investor maneuver through the treacherous waters controlled by Hedge Funds and Market Makers. From the EXPstocktrader.com website you will find an offering for a newsletter that gives interested followers several trading ideas and stock lessons on a monthly basis. SA followers only see a very small part of EXP's published research.
This is not an easy business. Wall Street trickery is at an "All Time High" these days; brutally fierce and rampant against small retail investors. Trading is psychological in nature, meaning that the market's psychological warfare can be extremely debilitating. EXP works hard to identify and write about current stock opportunities in the market that can produce some huge gains from disconnects in stock prices. These inefficiencies can be taken advantage of if you can properly identify opportunities and then manage to act on them.
EXP resides in the USA, and is thankful to followers worldwide.
You can also follow EXPstocktrader on:
Twitter --- @EXPstocktrader
Website --- http://www.EXPstocktrader.com
Email --- firstname.lastname@example.org
Disclosure: The administrator(s) of the services mentioned here may be long, short, or flat in any position mentioned. All statements are made without any representation to its complete accuracy and administrator(s) are not compensated for posting notes by listed companies. Some compensation is paid by SA if the article gets picked for circulation, that's it. Prices shown are approximate. Ratings may change at any time. All posts are for simulation purposes only. All stock trades transacted by you are at your own risk. We trade stocks and do not usually buy and hold indefinitely. Please take any information that you see here and consult your own investment advisor before making any real trades. EXP, EXPstocktrader.com and SA are Not licensed to give you investment advice based on your own personal suitability and risk tolerances. Please consult with your financial advisor before making any trades that you read about here or anywhere EXPstocktrader publishes information for that matter. Thank you.
I'm a business graduate with an interest in discovering and writing about healthy investments, which are primarily focused on the healthcare sector.
The stock exchange is a fascination for me and I love to write about any aspect of it.
Strategic investor/researcher with a primary focus in high percentage gain poised long equity investments. My research areas include the biotech/pharmaceutical sector, precious metals markets, short equities and natural resources.
Our investment philosophy primarily resides in buying equities for long term investments. However, we do enter trading positions primarily in the options and futures market to take advantage of situations as they arise (VIX and energy trades).
Our background includes:
-Applied science perspective with an Engineering background
-Health science perspective with a Registered Nurse background
-Finance perspective with an MBA background
Consultant / Investment research writer, focusing on natural resource companies & select other small cap opportunities. MBA, Financial Analysis, Top 12 rated business school, New York University (NYU) Stern School of Business.
Designated a Chartered Financial Analyst, "CFA" He's published hundreds of investment articles & CEO interviews on a number of prominent [Metals & Mining] and [Investment] websites including:
EpsteinResearch, InvestorIdeas, InvestingNews, MiningFeeds, Equity.Guru, Investing.com, Equities.com, CNAFinance, CountingPips, StockHouse, SeekingAlpha, TalkMarkets, CEO.CA, Investor-SMS.de, SmallCapMarkets.
On Twitter: @peterepstein2 Email: email@example.com
Private investment analyst and writer with an interest in companies with emerging technologies oriented towards improving healthcare, alternative investments, emerging markets, and technology.